News and Trends 20 Jul 2022 Upstaza gets nod from Europe for AADC deficiency treatment PTC Therapeutics, Inc. says Upstaza (eladocagene exuparvovec) has been given marketing authorization by the European Commission. Upstaza is the first approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency, and the first marketed gene therapy directly infused into the brain. It is approved for patients 18 months and older. “Today’s approval from the European […] July 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2022 LabShares Newton doubles space for biotech startups and launches pitch contest LabShares Newton has opened 19,000 square feet of new incubator lab space for startup biotechs and expects to open another 6,000-foot lab in September. LabShares’ new space incorporates 12 private suites, 15 lab benches in the open lab, and a comprehensive set of shared resources and equipment. All private suites have already been committed to […] July 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2022 ICL and PlantArcBio look to use RNAi to boost crop yields ICL, a global specialty minerals company, and ag-biotech company PlantArcBio, Ltd., have announced the development of a novel bio-stimulant technology platform to improve crop yields while having a minimal impact on the environment. The platform uses RNAi (RNA interference) technology to maximize a plant’s natural yield increase mechanisms, without any genetic modification, and was the […] July 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2022 WuXi Biologics to build new center in Singapore as part of $1.4B investment WuXi Biologics, a global contract research, development and manufacturing organization (CRDMO), has announced a 10-year $1.4 billion investment plan. The plan aims to expand the company’s research, development, and large-scale drug substance and drug product (DS/DP) manufacturing capacity and capabilities in Singapore. The company will build a new site that will add 120,000L biomanufacturing capacity […] July 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2022 Alpenglow Biosciences and CorePlus partner to bring 3D spatial biology to clinical R&D Spatial biology company Alpenglow Biosciences is partnering with CorePlus, a high complexity CLIA-certified clinical and anatomic pathology laboratory, to digitize and analyze tissues in 3D to deliver novel spatial biology insights and accelerate drug development. As part of the partnership, CorePlus will invest in Alpenglow and receive access to Alpenglow’s 3Deep Imager, a hybrid open […] July 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2022 eureKARE launches synthetic biology studio network eureKARE, a company focused on financing and building next generation biotech companies in the fields of synthetic biology, has launched its first synthetic biology studio in Belgium. In conjunction with this, eureKARE has appointed Georges Rawadi as chief of biotech studio development. eureKARE said its thematic synthetic biology studio model is a novel, flexible approach […] July 19, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2022 Cells for Cells treats first patient with exosome-produced therapy for osteoarthritis Cells for Cells (C4C), a clinical-stage biotech allogeneic stem cell and stem-cells-derived therapeutics for high-impact chronic diseases, has announced a six-month follow-up of the clinical data from the first patient dosed with an exosome-produced therapy for osteoarthritis. The results were made public at an extracellular vesicles signature series during the ISCT annual meeting in San […] July 19, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2022 SINOVAC starts influenza vaccine trial in Chile Sinovac Biotech Ltd., a provider of biopharmaceutical products in China, has initiated a phase III clinical trial for SINOVAC’s inactivated quadrivalent influenza vaccine in Chile through a collaboration with the Pontificia Universidad Católica de Chile. SINOVAC said the results aim to provide scientific evidence to support its influenza vaccine immunogenicity and protection capacity. This clinical […] July 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2022 SK Bioscience signs deal with Novavax to manufacture COVID-19 vaccine South Korean company SK Bioscience has extended its partnership with Novavax, Inc., a U.S. biotechnology company specializing in next-generation vaccines, for the manufacturing and supply of Novavax COVID-19 vaccine targeting Omicron variants in prefilled syringes. SK Bioscience and Novavax signed an agreement for the technology transfer of Novavax proprietary COVID-19 variant antigen materials and manufacturing […] July 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 FORTY51 Ventures closes $43M biotech fund and announces first investment FORTY51 Ventures has announced the closing of FORTY51 Ventures I, raising $43 million in its first close. FORTY51’s core strategy focuses on company formation and early-stage investments in biotech with geographic emphasis on Switzerland, France and Germany. FORTY51 Ventures will lead or co-lead early rounds (seed and series A) of its growing portfolio, which will […] July 18, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 Ginkgo Bioworks to collaborate with Sumitomo Chemical on animal-free personal care ingredient Cell programming company Ginkgo Bioworks has launched a new cell programming project as part of a broader collaboration with Japanese company Sumitomo Chemical Co., Ltd. Through the partnership, Sumitomo Chemical will leverage Ginkgo’s codebase and expertise in organism engineering to produce molecules in a sustainable way for products across a broad range of industries. The […] July 18, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 Oxford Science Enterprises raises £250M Oxford Science Enterprises (OSE), the independent investment company created to found, fund and build transformational businesses via its partnership with the University of Oxford, has raised a further £250 million ($300 million) in funding. This brings the total amount raised by OSE to more than £850 million ($1 billion) since inception in 2015. These funds […] July 18, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email